Liver fibrosis is a pathological condition in which chronic inflammation and changes to the extracellular matrix lead to alterations in hepatic tissue architecture and functional degradation of the liver. Inhibitors of the enzyme soluble epoxide hydrolase (sEH) reduce fibrosis in the heart, pancreas and kidney in several disease models. In this study, we assess the effect of sEH inhibition on the development of fibrosis in a carbon tetrachloride (CCl 4 )-induced mouse model by monitoring changes in the inflammatory response, matrix remolding and endoplasmic reticulum stress. The sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) was administered in drinking water. Collagen deposition in the liver was increased five-fold in the CCl 4 -treated group, and this was returned to control levels by TPPU treatment. Hepatic expression of Col1a2 and 3a1 mRNA was increased over fifteen-fold in the CCl 4 -treated group relative to the Control group, and this increase was reduced by 50% by TPPU treatment. Endoplasmic reticulum (ER) stress observed in the livers of CCl 4 -treated animals was attenuated by TPPU treatment. In order to support the hypothesis that TPPU is acting to reduce the hepatic fibrosis and ER stress through its action as a sEH inhibitor we used a second sEH inhibitor, trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB), and sEH null mice. Taken together, these data indicate that the sEH may play an important role in the development of hepatic fibrosis induced by CCl 4 , presumably by reducing endogenous fatty acid epoxide chemical mediators acting to reduce ER stress.
Introduction
Liver fibrosis is a pathological condition that results from a normally beneficial wound healing process (Hernandez-Gea and Friedman, 2011) . Damage to the liver triggers the inflammatory response, which initiates recruitment of macrophages and fibrocytes and remodeling of the extracellular matrix (ECM) in order to clear damaged cells and preserve the architecture of the liver (Bataller and Brenner, 2005) . However, repeated injury, such as occurs in chronic alcoholism, exposure to environmental toxins, and viral infection can lead to a cascade of inflammatory system-related changes in the liver that result in abnormal deposition and composition of collagens and other elements of the ECM, as well as extensive damage to the tissue (Iredale, 2007) . This pathological condition is called fibrosis.
Fibrosis is facilitated by a number of signaling molecules that modulate the immune response such as the cytokines IL-6 and IL-1β and the growth factor TGFβ (Wynn and Ramalingam, 2012) . Alongside these commonly studied protein inflammatory mediators, bioactive lipids play an important role (Funk, 2001; Stables and Gilroy, 2011) . There is growing evidence of the importance of lipid signaling in liver fibrosis. The eicosanoids are a class of lipid mediators that include the leukotrienes, prostaglandins and epoxyeicosatrienoic acids (EETs), produced through the activity of lipoxygenase (LOX), cyclooxygenase (COX) and cytochrome P450 enzymes, respectively (Funk, 2001; Stables and Gilroy, 2011) . The leukotrienes and prostaglandins have been implicated in the progression of liver fibrosis in studies employing leukotriene receptor antagonists and COX inhibitors. A leukotriene receptor antagonist, montelukast, attenuates liver damage and fibrosis in a bile duct ligation (BDL) and resection rat model (El-Swefy and Hassanen, 2009) . A COX inhibitor, meloxicam, reduces fibrosis in this same model (Kim et al., 2008) , although contradictory results have been reported using celecoxib (Yu et al., 2009) .
A third class of arachidonic acid-derived mediators, the EETs, display anti-inflammatory and anti-fibrotic properties (Stables and Gilroy, 2011) . The EETs are metabolized by soluble epoxide hydrolase (sEH), producing dihydroxy molecules that are less lipophilic and more readily Toxicology and Applied Pharmacology 286 (2015) [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] conjugated, leading to their removal from the site of action . sEH inhibitors modulate the levels of epoxy fatty acids (EpFAs) in tissues and dramatically reduce acute systemic inflammation in LPS-induced models as well as attenuate fibrosis and inflammation in the heart, kidney and pancreas (Li et al., 2008; Iyer et al., 2012; Kompa et al., 2013; Sirish et al., 2013) . In diabetic models, sEH inhibitors display organ protective properties, reducing islet cell apoptosis in the pancreas and tissue damage in the liver (Iyer et al., 2012) . It has been hypothesized that these inhibitors act by blocking the major route of metabolism of organ protective and anti-inflammatory EpFA (Iyer et al., 2012) . Given these reported findings, we evaluated a sEH inhibitor in a murine model of liver fibrosis.
Once activated by metabolism, carbon tetrachloride (CCl 4 ) causes damage to the liver through lipid peroxidation, resulting in an upregulation of pro-inflammatory pathways and eventual fibrosis (Iredale, 2007) . EpFAs have been implicated in this model. Both COX-2 and 5-LOX inhibitors have been found to reduce fibrosis after CCl 4 treatment, and when used in combination, reduce both inflammation and necrosis (Horrillo et al., 2007) , though there are contradictory results when different COX-2 inhibitors are employed, as in the BDL model of fibrosis (Hui et al., 2006) . Dietary supplementation with arachidonic acid and the omega-3 docosahexaenoic acid (DHA) has been found to attenuate fibrosis in an ethanol-induced model of liver damage (Song et al., 2008) .
A growing body of evidence indicates that endoplasmic reticulum (ER) stress is a contributor to fibrotic diseases (Mollica et al., 2011; Lenna and Trojanowska, 2012; Tanjore et al., 2012) . Directly relevant to this study, recent reports have demonstrated an increase in ER stress in rodents injected with CCl 4 (Ji et al., 2011; Lee et al., 2011; Jin et al., 2013) . However, the link between the development of hepatic fibrosis and ER stress is still poorly understood. The ER is highly responsive to nutrients and to the energy state of the cell. It plays an important role in folding of newly synthesized proteins. When the folding capacity of the ER is exceeded, misfolded proteins accumulate and lead to ER stress (Schroder and Kaufman, 2005) . Cells use adaptive mechanisms to counter the deleterious effects of ER stress known as the unfolded protein response (Kaufman et al., 2002) . The unfolded protein response consists of three major branches that are controlled by the ER transmembrane proteins PKR-like ER-regulated kinase (PERK), inositol requiring protein 1α (IRE1α), and activating transcription factor 6 (ATF6) (Hotamisligil, 2010; Hummasti and Hotamisligil, 2010; Ron and Walter, 2007) . In particular, the IRE1α sub-arm of ER stress signaling is critical for the unfolded protein response in fibrotic tissues (Chiang et al., 2011; Martino et al., 2013) . The various unfolded protein response sub-arms synergize to attenuate stress by increasing the folding capacity of the ER (Schroder and Kaufman, 2005) . However, if the compensatory mechanisms fail to facilitate the adaptation of cells to ER stress, induction of the unfolded protein response can lead to elimination of stressed cells by apoptosis (Zinszner et al., 1998; Nishitoh et al., 2002) . We recently demonstrated that sEH deficiency or pharmacological inhibition in mice attenuated chronic high fat diet-induced ER stress in liver and adipose tissue in a cell autonomous manner (Bettaieb et al., 2013) .
Based on the above information we examined markers of ER stress in our murine model of liver fibrosis and asked if they could be reduced by treatment with sEH inhibitors.
Materials and methods
Reagents. TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea) (Rose et al., 2010) and t-TUCB (trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid), (Hwang et al., 2007) were synthesized and the physical properties were assessed as previously reported. Antibodies for pPERK (Thr980), PERK, peIF2α (Ser51), eIF2α, sXBP1, ATF6, IRE1α, and BiP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) while phosphop38 (Thr180/Tyr182), p38, pJNK (Thr183/Tyr185), JNK and cleaved caspase3 antibodies were from Cell Signaling (Beverly, MA). Antibodies for pIRE1α (Ser724) were purchased from Abcam (Cambridge, MA). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from BioResources International (Carlsbad, CA). Unless otherwise indicated, all other chemicals were purchased from Sigma (St. Louis, MO).
Animals. All animal studies were approved by the University of California Davis Animal Use and Care Committee and were performed in accordance with the National Institutes of Health guide for the care and use of laboratory animals. Male C57BL (20 g) were obtained from Charles River Laboratories (Wilmington, MA). A colony of C57BL mice with a disruption in the sEH gene resulting in a functional knockout is maintained by the UC Davis Mouse Biology Program (Luria et al., 2007) . Mice were divided into four groups of 8: The Control group was given intraperitoneal injections (I.P.) of sterile filtered Neobee M-5 (Fisher Scientific, Houston, TX) every five days for five weeks, for a total of 7 injections. They also received drinking water containing 1% PEG-400 (Fisher Scientific). The CCl 4 -only group was given I.P. injections of 197 mg/kg CCl 4 (Sigma) mixed 1:7 in sterile filtered Neobee M-5 every five days for five weeks, for a total of 7 injections. This dose and route of administration was chosen since it has been shown to induce robust fibrosis in C57BL mice (Constandinou, et al., 2005) . They received drinking water containing 1% PEG-400 (Fisher Scientific). The CCl 4 + TPPU group was treated with CCl 4 similar to the CCl 4 -only group and received drinking water with 10 mg/L TPPU and 1% PEG-400, prepared as follows. TPPU was dissolved in PEG-400 to give a 1000 mg/L clear solution. This solution was then added to warm drinking water with rapid stirring to give the 10 mg/L solution of TPPU in 1% PEG-400 in drinking water. The water was provided ad lib. The TPPU-only group was given I.P. injections of sterile filtered Neobee M-5 like the Control group, and received drinking water containing TPPU similar to the CCl 4 + inhibitor groups. In the experiment with the second sEH inhibitor, t-TUCB was solubilized in PEG-400 and then added to drinking water, resulting in a final concentration of 10 mg/L TPPU and 1% PEG-400. Based on estimated daily water consumption, a concentration of 10 mg/L inhibitor in drinking water will result in a dose of approximately 1.7 mg/kg/day. The mice were euthanized three days after the final injection.
Histology. Liver samples were embedded, sectioned and stained by the UC Davis Veterinary Medical Teaching Hospital Anatomic Pathology Service (Davis, CA). The slides were imaged using a Nikon Diaphot inverted microscope and quantified using ImageJ (NIH, Bethesda, MD).
Protein analysis. Mouse tissues were dissected and immediately frozen in liquid nitrogen. For zymography, liver samples were homogenized in cold 25 mM Tris-HCl buffer using 3 × 30 s bursts of a roto-stator homogenizer with one minute intervals in between. Zymography was performed using Novagen pre-cast gelatin zymography gels (Invitrogen, Carlsbad, CA) according to manufacturer's instructions and quantified using ImageJ (NIH). For Western blots, tissues were ground in the presence of liquid nitrogen and lysed using radio-immunoprecipitation assay (RIPA) buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% sodium dodecyl sulfate [SDS], 1% Triton X-100, 1% sodium deoxycholate, 5 mM EDTA, 1 mM NaF, 1 mM sodium orthovanadate and protease inhibitors). Lysates were clarified by centrifugation at 10,000 ×g for 10 min and protein concentrations were determined using a bicinchoninic acid protein assay kit (Thermo Scientific, Waltham, MA). Proteins were resolved by SDS-PAGE and transferred to PVDF membranes. Immunoblots were performed with the relevant antibodies. Proteins were visualized using Luminata™ Forte (Millipore, Billerica, MA). For quantitation purposes, pixel intensities of immuno-reactive bands from blots that were in the linear range of loading and exposure were quantified using FluorChem 9900 (Alpha Innotech, San Lenardo, CA). LC-MS/MS analysis of plasma oxylipins. Plasma oxylipins were extracted and analyzed by LC-MS/MS as previously described (Yang et al., 2009 ). Blood levels of inhibitors were determined by LC-MS/MS as previously described . Retention time, selected reaction monitoring and internal standard information used to quantify all analytes are in the supplementary materials Table S1 .
LC-MS/MS analysis of hydroxyproline. The quantification of hepatic tissue hydroxyproline by LC-MS/MS was performed using the method developed by Kindt et al. (2003) with the following changes. The analysis was carried out using a Micromass Quattro Ultima triple quadrupole tandem mass spectrometer (Micromass, Manchester, UK) equipped with an electrospray ionization interface. The HPLC system consisted of a Waters model 2790 separations module (Waters, Milford, MA) equipped with a Waters model 2487 dual-wavelength absorbance detector. The mass spectrometer was coupled to the outlet of the HPLC (Pursuit C18, 2.0 × 150 mm, 3 μm column (Agilent, Englewood, CO)).
Statistical analysis. All data are expressed as mean ± standard error. The Student's t-test was used to test for differences in groups in all experiments. Statistical analyses were performed using Excel (Microsoft, Redmond, WA). Differences were considered significant with Pvalue b 0.05 or lower. Sample size "N" refers to the number of animals.
Results

Administration of the sEH inhibitor TPPU reduced CCl 4 -induced collagen deposition and collagen mRNA expression
Animals were treated with CCl 4 for five weeks to induce liver fibrosis. To potentially reduce development of this fibrosis, the sEH inhibitor TPPU was chosen due to its potency on and selectivity for the sEH target and because of its ADME properties in mice . TPPU was administered in drinking water starting with the first CCl 4 injection, and blood levels of the compound were assessed at 2.5 weeks and at the termination of the experiment. At both time points, taken at 8 AM from mice on a 7 AM to 7 PM light cycle, the TPPU-treated concentration of the inhibitor was approximately 500 nM (2.5 wk = 511 ± 37 nM, 5 wk = 543 ± 17 nM). All experimental groups gained weight during the six week experiment (supplementary materials). The CCl 4 -only and TPPU-only groups displayed a greater weight gain than the CCl 4 + TPPU and Control groups. Three days after the last injection of CCl 4 , the livers were removed and prepared for protein, mRNA, and histological analysis. Sections were stained with picrosirius red (Fig. 1A) .
The percent area stained by picrosirius red relative to the Control group increased five-fold in the CCl 4 -only group, while the CCl 4 + TPPU group returned to the level of the Control group (Fig. 1B) . The CCl 4 -only group displayed a roughly six-fold increase in total hepatic tissue hydroxyproline as determined by LC-MS/MS (Fig. 1C) . The CCl 4 + TPPU group was not statistically different (P-value N 0.05) from either the Control or the CCl 4 -only groups (Fig. 1C) . Staining for alpha smooth muscle actin (α-SMA) revealed an increase in percent area stained in the CCl 4 -only group relative to the Control group that was not significantly altered by TPPU treatment (supplementary materials Fig. S2 ). A PCR array experiment (described in detail below) determined that the messages for collagens 1a2 and 3a1 were upregulated approximately sixteen fold in the CCl 4 -only group (Fig. 3) . The upregulation was reduced by 50% in the CCl 4 + TPPU group. This indicates that TPPU treatment has an effect on both the expression and deposition of collagen due to CCl 4 treatment.
Administration of the sEH inhibitor TPPU modulated the mRNA expression and activity of MMPs and the mRNA expression of other components of the ECM In order to assess the signaling pathways involved in the anti-fibrotic effect of TPPU treatment, a PCR array was run that included growth factors, cytokines, chemokines and components of the ECM involved in the progression of fibrosis. When compared to the Control group, the CCl 4 -only group displayed 33 genes upregulated 1.5 fold or more with a P-value of 0.5 or lower (Fig. 2) . The CCl 4 + TPPU group displayed 20 genes upregulated 1.5 fold or more with a P-value of 0.5 or lower compared to the Control group (Fig. 2) . The thirteen genes that differentiated the CCl 4 -only and CCl 4 + TPPU groups with a P-value of 0.5 or lower are displayed in Fig. 3 . To validate these results, the mRNA expression of three genes included in the array were independently determined by RTPCR and found to display the same trend as reported by the array (supplementary materials Table S3 ). Compared to the CCl 4 -only group, the CCl 4 + TPPU group displayed a decrease in mRNA expression of MMP-2, -8, -9, -13, and -14 (Fig. 3) . The largest reduction occurring for MMP-8 and MMP-9, which were decreased approximately four-fold with respect to the CCl 4 -only group. MMP-1a was increased by approximately two-fold in the CCl 4 -only and CCl 4 + TPPU groups compared to control (supplementary materials Table S2 ). Of the tissue inhibitors of metalloproteases (TIMPs), only TIMP-2 showed a statistically significant (P-value b 0.05) modulation in the CCl 4 -only group relative to the Control group (supplementary materials Table S2 ). In the CCl 4 -only and CCL 4 + TPPU groups, TIMP-2 expression was upregulated 3.5 and 2.5 fold, respectively. The modulation of the expression of several MMPs prompted us to examine MMP activity in the hepatic tissues. Using a randomly selected subset of samples from the experimental groups, we performed gelatin zymography, which assays MMP-1, -2 and -9 activity, primarily (Snoek-van Beurden and Von den Hoff, 2005) . Intracellular pools of MMP-1a, -2, and -9 contain both pro-and activeforms of the enzymes, the active form is produced when a roughly 10 kDa peptide is cleaved from the pro-form. In zymography, the enzymes are separated by native PAGE and then both forms of the enzymes are activated. We detected an increase in gelatinase activity in the CCl 4 -only group in the 90-107 kDa range relative to the Control group, which spans the molecular weight of the 92 kDa pro-MMP-9 (Fig. 4) . This activity was reduced in the CCl 4 + TPPU group. We also detected a large increase in gelatinase activity in the 45 -54 kDa range in the CCl 4 + TPPU group relative to the Control group, corresponding to the molecular weight of active MMP-1a, which has a roughly 57 kDa pro-form and a 48 kDa active form (Balbin et al., 2001 ). This activity was only slightly increased in the CCl 4 -only group. We also detected a moderate increase in gelatinase activity in the 62-69 kDa molecular weight range in the CCl 4 -only and CCl 4 + TPPU groups, corresponding to active MMP-2, which is roughly 62 kDa (supplementary materials Fig. S3 ). TPPU treatment significantly modulated the mRNA expression of two other components of the ECM, integrin α2 (Itgα2) and Thrombspondin 2. The three-fold induction in Itgα2 between the CCl 4 -only and Control group was reduced by almost 50% in the CCl 4 + TPPU group (Fig. 3) . Thrombspondin 2 was increased almost six-fold in the CCl 4 -only group relative to the Control group. This increase was attenuated by 33% in the CCl 4 + TPPU group (Fig. 3) .
Administration of TPPU modulated the inflammatory response
Of the chemokines and chemokine receptors in the PCR array, two receptors, C-C chemokine receptor 2 and C-X-C motif chemokine receptor-4 were significantly reduced in the CCl 4 + TPPU group relative to the CCl 4 -only group (Fig. 3) . C-C chemokine receptor 2 was increased over five-fold in the CCl 4 -only group relative to the Control group, and this increase was almost halved in the CCl 4 + TPPU group. Similarly, an over 4-fold increase in C-X-C motif chemokine receptor-4 mRNA expression in the CCl 4 -only group relative to the Control group was reduced by 50% in the CCl 4 + TPPU group. The PCR array also revealed that an almost 2 fold increase in TGFβ1 in the CCl 4 -only group relative to the Control group was decreased to control level in the CCl 4 + TPPU group (Fig. 3) .
Since sEH inhibitors have been shown to modulate the inflammatory EpFA in other disease models, we examined blood levels of oxylipids (supplementary materials Table S4 , Figs. S4, and S5). We did not see a statistically significant difference in most classes, including the EETs. However, one lipid mediator, the 12-LOX metabolite 12-HETE, was increased over 3-fold in the CCl 4 group. Levels of this EpFA were reduced in the CCl 4 + TPPU group, but did not reach statistical significance.
Administration of TPPU attenuated CCl 4 -induced ER stress
ER stress is an emerging factor in fibrotic diseases and a number of studies have identified significant correlation between hepatic fibrosis and ER stress (Mollica et al., 2011; Lenna and Trojanowska, 2012; Tanjore et al., 2012) , although the precise mechanism is not clear. In this study we investigated whether exposure to CCl 4 induces hepatic ER stress in vivo and evaluated the effects of sEH pharmacological inhibition on CCl 4 -induced hepatic ER stress. In line with published studies exposure to CCl 4 induced ER stress (Lewis and Roberts, 2005; Lee et al., 2011; Jin et al., 2013) (Fig. 5A ). In line with these findings, hepatic mRNA of BiP, sXBP1 ATF4, ATF6 and CHOP was decreased upon pharmacological inhibition of sEH compared with CCl 4 -treated mice, indicating attenuated ER stress (Fig. 5B) .
Excessive ER stress leads to the induction of inflammatory responses and eventually cell death (Zha and Zhou, 2012) . In addition, CCl 4 -induced liver injury has been shown to involve TNF-α-and TGF-β-mediated activation of JNK and cell death (Hong et al., 2013; Ma et al., 2014; Wu and Cederbaum, 2013) . Thus, we investigated the effects of pharmacological inhibition of sEH on CCl 4 -induced inflammation. Consistent with previous reports, induction of liver fibrosis correlated with increased hepatic JNK and p38 phosphorylation (Fig. 5C ). On the other hand, sEH pharmacological inhibition reduced CCl 4 -induced phosphorylation of JNK and p38 (Fig. 5C ). After exposure to apoptotic stimuli, cells activate initiator caspases that proteolytically cleave and activate effector caspases (such as caspase-3) to dismantle the dying cell. Caspase3 is implicated in ER stress-induced cell death (Zhang et al., 2011a,b) . Accordingly, we determined ER stress-induced expression of active caspase-3 in CCl 4 -treated mice versus mice with combined treatment (CCl 4 + TPPU). Consistent with published reports (Chan et al., 2013; Moran-Salvador et al., 2013) , treatment with CCl 4 caused a significant increase in the expression of the active form of caspase3 whereas sEH inhibition significantly decreased CCl 4 -induced caspase-3 activation (Fig. 5D) . Together, these results indicate that the pharmacological inhibition of sEH can provide a protective mechanism against CCl 4 -induced ER stress in the liver.
Disruption of the sEH gene or administration of an alternate sEH inhibitor reduced collagen deposition
In order to support the hypothesis that TPPU is acting to reduce the hepatic fibrosis and ER stress through its action as a sEH inhibitor, wild-type mice were treated with a second sEH inhibitor with a different structure, trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB). Blood levels of the compound were determined using the procedure described above for TPPU and found to be 440 ± 36 nM midway through the experiment (2.5 week time point) and 481 ± 23 nM at the end (5 week time point.) The t-TUCB treated animals displayed a roughly 25% reduction in collagen deposition as determined by picrosirius red staining (Figs.  6A and B) .
Quantification by LC-MS/MS revealed that the total tissue hydroxyproline levels in the livers from t-TUCB treated animals were not statistically different from either the Control group or the CCl 4 -only group (P-value N 0.05) (Fig. 6C) . To further test the involvement of the sEH, C57BL mice with a disruption in the gene for sEH were treated with CCl 4 , TPPU, or both. The hydroxyproline levels in the livers of the CCl 4 -treated Null animals were not statistically different (Pvalue N 0.05) than the Null Control group, wild-type Control, or the wild-type CCl 4 -only group (Fig. 6C) . However, the CCl 4 -treated Null animals displayed significantly less (P-value b 0.05) collagen deposition as judged by picrosirius red staining, comparable to the CCl 4 + t-TUCB group (Figs. 6A and B) . The Null + CCl 4 + TPPU group did not show significant differences (P-value N 0.05) in the hydroxyproline levels or the collagen deposition from the Null + CCl 4 group (Fig. 6 ).
Discussion
In this study, the inhibition of sEH, the major route of metabolism for EpFA such as the EETs, resulted in a dramatic attenuation of many markers of liver fibrosis and ER stress associated with CCl 4 treatment. TPPU has an IC 50 of 8.3 nM when assayed with the recombinant murine enzyme and cyano(2-methoxynaphthalen-6-yl)methyl(3-phenyloxiran-2-yl)methyl carbonate (CMNPC) as the substrate , so the plasma levels of TPPU in this study were well above the concentration Table S2 . Fig. 3 . TPPU treatment significantly downregulates the hepatic mRNA expression of thirteen genes compared to the CCl 4 -only group. PCR array analysis of hepatic tissues after 5 weeks of CCl 4 treatment. TPPU was administered in drinking water starting with CCl 4 treatment. The genes displayed a 1.5 fold upregulation or higher in the CCl 4 -only group relative to the Control group, and a concomitant downregulation in the CCl 4 + TPPU versus the CCl 4 -only group with a P-value of 0.05 or lower. *P-value vs. Control group ≤ 0.05; **P-value vs. Control group ≤ 0.01;~P-value vs. CCl 4 -only group ≤ 0.05;~~P-value vs. CCl 4 -only group ≤ 0.01. N = 6-8 animals per group. required to inhibit the enzyme. TPPU treatment not only altered collagen density, but also the composition of the ECM, reducing collagen deposition and collagen 1a2 and 3a1 mRNA expression in the CCl 4 + TPPU group compared to the CCl 4 -only group. These changes were accompanied by dramatic shifts in MMP activity and expression, although TPPU did not alter the upregulation of TIMP-2 observed in the CCl 4 -only group. Taken together, the decrease in collagen deposition and differences in expression patterns of collagen isoforms and MMPs between the CCl 4 + TPPU and CCl 4 -only groups indicate that the ECM in the CCl 4 + TPPU group more closely resembles the control tissue. The shifts in MMP expression, especially, may have implications for tissue regeneration and recovery from fibrosis, where there is evidence that sEH plays a role. A recent study reported that treatment with a sEH inhibitor increased liver to body weight ratio after partial hepatectomy and sEH null mice displayed accelerated skin wound healing (Panigrahy et al., 2013) . Regenerative physiological processes like these are facilitated by ECM reorganization and construction, which require changes in MMP activity.
Our zymography yielded unexpected results. We detected a modest increase in pro-MMP-9 activity in the CCl 4 -only group that was attenuated by TPPU treatment and no change in MMP-2 activity. Upregulation of MMP-9 expression and increased MMP-9 activity have been associated with the progression of liver fibrosis in both human and rodent (Kurzepa et al., 2014) , and therefore reduction in MMP-9 activity should attenuate pro-fibrotic matrix remolding. By far, the most striking result was the dramatic increase in gelatinase activity in the 45-54 kDa range in the TPPU + CCl 4 group relative to all other groups. This molecular weight range corresponds to active MMP-1a (Balbin et al., 2001 ). MMP-1a, first characterized in 2001, has been primarily investigated in the context of cancer, where knockout of the gene causes an increase in tumor growth and angiogenesis in a Lewis lung carcinoma mouse model (Fanjul-Fernández, et al., 2013; Foley et al., 2014) . The role that MMP-1a may play in the observed anti-fibrotic effects of sEH inhibition is currently under investigation.
While the change in most inflammatory cytokines and growth factors did not pass the statistical test, TGFβ1 was substantially reduced in the CCl 4 + TPPU group relative to the CCl 4 -only group. TGFβ impacts fibrosis through multiple mechanisms including the modulation of MMP and TIMP expression and the stimulation of the production of matrix components such as the collagens and integrin α2 (Baghy et al., 2012) . The reduction of TGFβ in the TPPU + CCl 4 relative to the CCl 4 -only group is further indirect evidence of the changes to the ECM elicited by sEH inhibition. Our observation parallels a result obtained in a rat diabetic model of kidney fibrosis, in which the elevation of TGFβ in the fibrotic kidney was reduced by administration of a sEH inhibitor (Elmarakby et al., 2013) . It should be noted that these mRNA expression data may not reflect hepatic protein or enzymatic activity levels.
Because sEH inhibition changes oxylipid metabolism, we examined plasma levels of EpFA. Despite a high degree of variation, 12-HETE was identified as a potential marker of CCl 4 -induced liver fibrosis. 12-HETE has been previously identified in the sputum of patients with cystic fibrosis (Yang et al., 2012) . It is generated by 12-lipoxygenase (12-LOX), which has been studied in the context of cardiac hypertrophy and fibrosis. Overexpression of 12-LOX in rat cardiac fibroblasts results in increased collagen and fibronectin secretion (Wen et al., 2003) .
Recent studies provided evidence that ER stress can affect production of the extracellular matrix and consequently the progression of fibrotic diseases (Mollica et al., 2011; Lenna and Trojanowska, 2012; Tanjore et al., 2012) , including hepatic fibrosis that results from the injection of CCl 4 (Ji et al., 2011; Lee et al., 2011; Jin et al., 2013) . In a nonalcoholic steatohepatitis methionine-choline-deficient diet-induced model, liver fibrosis correlated with the increased expression of BiP and activation of caspases 12 and 7 (Mu et al., 2009 ). Moreover, soluble mediators secreted mainly by the ER in steatotic hepatocytes and activated Kupffer cells mediate their trans-differentiation into myofibroblasts, which secrete fibrogenic cytokines and matrix components that trigger fibrosis (Yang et al., 2007; Mollica et al., 2011) . Indeed, fibrogenic activity in hepatic stellate cells increases upon induction of ER stress (HernandezGea et al., 2013) . Recently, we identified sEH as a regulator of ER stress in murine models of high fat diet-induced ER stress. sEH deficiency or pharmacological inhibition attenuated high fat diet-induced ER stress in liver and adipose tissues (Bettaieb et al., 2013) . In addition, sEH inhibition attenuates high fat diet-induced hepatic steatosis due to reduced inflammatory state (Liu et al., 2012) . sEH inhibition also prevents renal fibrosis through reduction of TGF-β and fibronectin expression in diabetic spontaneously hypertensive rats (Elmarakby et al., 2013) . Together, these data suggest that sEH contributes to ER stress-mediated TGF-β regulation of ECM production and trafficking. Genetic and chemical knockouts of the sEH as well as administration of EpFA alter a diversity of pathological states generally toward improved health. In several of these situations, now including CCl 4 -induced hepatic fibrosis, reduction in ER stress appears to be a common underlying mechanism.
In order to address if TPPU was targeting the sEH as its primary mechanism of reducing fibrosis and ER stress, two experimental strategies were employed. First, animals were treated with an alternative sEH inhibitor with a substantially different structure than TPPU, t-TUCB, which has an IC 50 of 11 nM when assayed with the recombinant murine enzyme and CMNPC as the substrate (Liu et al., 2013) . Second, sEH null mice were used. Both the CCl 4 + t-TUCB and Null + CCl 4 groups displayed a reduction in collagen deposition compared to the CCl 4 -only group, as judged by picrosirius red staining. Importantly, TPPU treatment in the null background did not yield a further reduction in fibrosis. Taken together, these data indicate that TPPU is producing the observed anti-fibrotic effects through inhibition of sEH. Hopefully, a better understanding of sEH function will provide new insight into the development of hepatic fibrosis due to exposure to carbon tetrachloride and other industrial and environmental chemicals. 
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